Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P W Armstrong

Showing results (231-240 of 281) with videos related to

Pageof 29
Sort By:
Nucleic Acids Research|November 25, 1980
A mammalian mitochondrial serine transfer RNA lacking the "dihydrouridine" loop and stemM H de Bruijn, P H Schreier, I C Eperon, et al.
The American Journal of Cardiology|December 1, 2001
Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-TrialB G Angeja, J H Alexander, R Chin, et al.
Journal of the American College of Cardiology|March 27, 2001
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromesM C Bahit, E J Topol, R M Califf, et al.
Journal of the American College of Cardiology|November 1, 1995
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary ArteriesG I Barbash, J Reiner, H D White, et al.
Circulation|November 3, 1998
Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb InvestigatorsP W Armstrong, Y Fu, W C Chang, et al.
Journal of the American College of Cardiology|June 1, 1989
Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarctionP W Armstrong, R S Baigrie, P A Daly, et al.
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
Journal of the American College of Cardiology|December 19, 1998
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trialK P Alexander, E D Peterson, C B Granger, et al.
Journal of the American College of Cardiology|June 17, 1998
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) InvestigatorsB K Metz, H D White, C B Granger, et al.
Journal of the American College of Cardiology|July 11, 1992
Remodeling and reparation of the cardiovascular systemK T Weber, P Anversa, P W Armstrong, et al.
Pageof 29

Showing results (231-240 of 281) with videos related to

Sort By:
Pageof 29
Nucleic Acids Research|November 25, 1980
A mammalian mitochondrial serine transfer RNA lacking the "dihydrouridine" loop and stemM H de Bruijn, P H Schreier, I C Eperon, et al.
The American Journal of Cardiology|December 1, 2001
Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-TrialB G Angeja, J H Alexander, R Chin, et al.
Journal of the American College of Cardiology|March 27, 2001
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromesM C Bahit, E J Topol, R M Califf, et al.
Journal of the American College of Cardiology|November 1, 1995
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary ArteriesG I Barbash, J Reiner, H D White, et al.
Circulation|November 3, 1998
Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb InvestigatorsP W Armstrong, Y Fu, W C Chang, et al.
Journal of the American College of Cardiology|June 1, 1989
Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarctionP W Armstrong, R S Baigrie, P A Daly, et al.
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
Journal of the American College of Cardiology|December 19, 1998
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trialK P Alexander, E D Peterson, C B Granger, et al.
Journal of the American College of Cardiology|June 17, 1998
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) InvestigatorsB K Metz, H D White, C B Granger, et al.
Journal of the American College of Cardiology|July 11, 1992
Remodeling and reparation of the cardiovascular systemK T Weber, P Anversa, P W Armstrong, et al.
Pageof 29